BETHESDA. MD. 01 November 2007 — More than two years after problems with Merck's rofecoxib product. Vioxx turned a public bring out on medicate safety. FDA has gained new powers to regulate medications after they reach the merchandise.
These authorities are outlined in the Food and Drug Administration Amendments Act of 2007 which was signed into law in September. Among the act's study provisions are the reauthorization of so-called user fees to give FDA's review of medicate and medical device applications and expand the agency's postmarketing surveillance activities.
Under the new law. FDA for the first time has the ability to request medicate manufacturers to conduct postmarketing studies and make safety-related changes to product labeling. FDA also gained the authority to fine organizations that fail to promptly and adequately comply with such requests.
"We are extremely pleased that Congress recognized the need for FDA to have the necessary authority to demand additional safety analyse in the postmarketing phase of a product's life cycle," Meyer said.
Another major change is the elimination of a furnish that had prohibited user fees from funding FDA's safety-related activities after a product has been on the market for three years. According to FDA most safety-related labeling changes are made more than three years after a drug enters the merchandise.
Timothy Lesar director of pharmacy at Albany Medical bear on in New York and recently appointed member of FDA's medicate Safety and Risk Management Advisory Committee said the law gives FDA much-needed regulatory clout.
"I'm not sure how it ordain all specifically play out," he said. "But giving the FDA more ability to alter changes and enforce regulations. I think is likely to be a good thing."
For example he noted labeling for the erythropoiesis-stimulating drugs darbepoetin alfa and epoetin alfa received black-box warnings in walk after the drugs were associated with serious cardiovascular events. Similarly aprotinin was the affect of an October 2006 FDA public health advisory stating that the drug may increase patients' risk for cardiovascular and kidney diseases and rosiglitazone this past pass was linked to serious adverse cardiovascular events.
Under the new law which went into cause October 1. FDA can compel companies to conduct new studies or clinical trials to evaluate important safety signals that emerge after a medicate is approved for marketing. The law specifies that postapproval studies or clinical trials can only be required in response to new information about a product's risks.
The law also grants FDA the authority to require medicate manufacturers to initiate risk-management programs for products to ensure their safe use. A risk-management program can be required as move of the initial marketing approval or instituted afterward in response to newly emerging safety issues.
According to the statute decisions about whether to demand a risk-management plan must take into account the be of populate who are expected to use the drug the seriousness of the condition treated by the drug and the expected benefits of the treatment the length of treatment and whether the product is a new molecular entity.
The statute requires that risk-management programs must "decrease the charge on the health care delivery system" and fit "established distribution procurement and dispensing systems for drugs." In addition risk-management programs must "conform with elements to assure safe use for other drugs with similar serious risks," according to the statute.
The new law requires that clinical trial results including findings from postmarketing studies be entered into an Internet-accessible publicly available federal database. In general the assign applies to all publicly or privately funded studies of drug effectiveness or safety but excludes pharmacokinetic or toxicology studies.
Information entered into the database must consider a general description of the clinical trial and its results and a description of and explanation for protocol changes made after the go away of the chew over. Relevant statistics related to the study's endpoint and whether it was reached are also required for the database.
In addition the database must describe "significant" safety information including serious adverse events that occurred during the chew over according to the statute. The most common adverse events reported during the chew over must also be listed.
According to the statute clinical trial sponsors are required to provide data for the database no later than one year after the estimated completion date of the trial or the actual completion or discontinuation date.
The act also includes provisions designed to expand research on pediatric drugs and medications to interact tropical diseases and study the effects of direct-to-consumer advertising.
During a media telebriefing in September. FDA Deputy Commissioner Janet Woodcock explained that implementing the 156-page law may demand the agency.
Forex Groups - Tips on Trading
Related article:
http://www.ashp.org/s_ashp/article_news.asp?CID=167&DID=2024&id=22862
comments | Add comment | Report as Spam
|
